Liver Cirrhosis Treatment Market Faces Major Shift Through 2036

The United States remains the dominant market for cirrhosis treatment, accounting for the highest share of the 7MM (seven major markets) in 2025. This demand is fueled by the rising prevalence of metabolic dysfunction-associated steatotic liver disease, alcohol-associated liver disease, and chronic hepatitis infections. While current medical interventions focus primarily on managing complications like portal hypertension and ascites, the focus is shifting toward agents that target the disease at its source.

Pharmaceutical developers are prioritizing antifibrotic and regenerative medicines to bridge the gap in therapeutic options. Key investigational candidates currently under observation include Akero Therapeutics' Efruxifermin, Galectin Therapeutics' Belapectin, and PharmaIN's PHIN-214. These therapies aim to interrupt fibrotic pathways and improve outcomes in patients with compensated cirrhosis. According to Sharad Chandra Vinayak of DelveInsight, the integration of precision medicine and biomarker-guided diagnostics will be critical in refining how these new treatments are deployed, moving the industry toward more personalized management strategies that could eventually reduce the clinical reliance on liver transplantation.